Byotrol Plc
("Byotrol" or the "Company")
Holdings in Company
Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, announces that it has received notification that as of 5 April 2024, Mr & Mrs D Newlands no longer have a notifiable interest in the Company's issued share capital.
For further information contact:
| Byotrol Plc | |
| Dr Trevor Francis, Non- Executive Chairman | +44 (0)1925 742 000 |
| David Traynor, Interim Chief Executive Officer Chris Sedwell, Chief Financial Officer
| |
| | |
| Cavendish Capital Markets Limited (Nominated Adviser and Broker) | +44 (0)20 7220 0500 |
| Geoff Nash/George Dollemore - Corporate Finance Nigel Birks/Harriet Ward - ECM | |
| | |
| | |
| Flagstaff Strategic and Investor Communications | +44 (0)20 7129 1474 |
| Tim Thompson/Andrea Seymour/Fergus Mellon
|
|
Notes to editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the animal and human healthare, industrial, institutional and consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.
For more information, go to byotrol.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.